Obesity, PEEP and Postoperative Oxygenation

Overview

A study on overweight patients undergoing anesthesia for laparoscopic surgery. – evaluation of positive end-expiratory pressure versus zero positive end-expiratory pressure during awakening on oxygenation in the early postoperative period.

Full Title of Study: “Zero Positive End-expiratory Pressure Before Emergence Improves Postoperative Oxygenation in Obese Patients Undergoing Laparoscopic Surgery – a Randomized Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Participant)
  • Study Primary Completion Date: January 25, 2023

Detailed Description

Positive end-expiratory pressure (PEEP) is often used during mechanical ventilation to preserve end-expiratory lung volume. After emergence and extubation, this volume will diminish instantly. Some patients will have difficulties to restore functional residual capacity (FRC) during the early phase of recovery. If routine high FIO2 is being delivered together with maintained PEEP prior to extubation, several important prerequisites are established for the development of postoperative atelectasis. The investigators hypothesize that establishing zero positive end-expiratory pressure (ZEEP) immediately prior to emergence preoxygenation, will prevent gas with high oxygen concentration from entering dorso-basal areas of the lungs, and thereby diminishing postoperative atelectasis formation and improve oxygenation. This randomized controlled study will study overweight patients undergoing general anesthesia for laparoscopic surgery. The patients in the two study groups will receive mechanical ventilation with identical settings, comprising low TV, PEEP, and no RM. Randomization will occur at the end of surgery, before awakening. The patients will be allocated to zero PEEP (ZEEP) or maintained PEEP during emergence preoxygenation and extubation. Importantly, the intervention group will have ZEEP established while still having low ETO2 levels, prior to any preoxygenation. Arterial blood gases will be collected before, during and after anaesthesia. Primary endpoint measure will be change in oxygenation from before awakening to after awakening.

Interventions

  • Procedure: ZEEP during awakening
    • ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
  • Procedure: PEEP during awakening
    • PEEP will be maintained throughout emergence preoxygenation and awakening.

Arms, Groups and Cohorts

  • Active Comparator: ZEEP during awakening
    • ZEEP will be used during emergence preoxygenation and awakening.
  • Active Comparator: PEEP during awakening
    • PEEP is maintained throughout emergence preoxygenation and awakening.

Clinical Trial Outcome Measures

Primary Measures

  • Change in oxygenation
    • Time Frame: Bloodgases will be obtained 5 minutes before the start of the awakening procedure and 30 minutes after awakening and extubation.
    • Arterial blood samples will be collected for measurement of arterial oxygen partial pressure.

Secondary Measures

  • Need for postoperative supplemental oxygen
    • Time Frame: First 3 hours postoperatively.
    • Number of patients and amount of oxygen needed in the respective group postoperatively.

Participating in This Clinical Trial

Inclusion Criteria

  • Obese patients scheduled for elective laparocopic surgery. – American Society of Anesthesiologists functional class I-III – Body Mass Index 35-50 kg/m2 Exclusion Criteria:

  • Body Mass Index ≥50 kg/m2 – Peripheral oxygen saturation (SpO2) breathing air <94 % – Symtomatic asthma, COPD or heart failure – Ischemic heart disease – Hemoglobin < 100g/l – Smokers and ex-smokers that stopped smoking < 9 months ago – Need for peroperative RM and PEEP higher than in study protocol, as indicated by SpO2 <92% despite the stipulated FiO2 0.30-0.35. – Obstructive sleep apnea syndrome on home-CPAP

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Region Västmanland
  • Provider of Information About this Clinical Study
    • Principal Investigator: Erland Ostberg, Consultant, principal investigator – Region Västmanland
  • Overall Official(s)
    • Erland Östberg, MD, PhD, Principal Investigator, Region Västmanland

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.